glp 1 pfizer pulls out of GLP-1 race after safety concerns Pfizer's Push into GLP‑1 Drugs

Diabetes leads to a significantly accelerated incidence of various related macrovascular complications, including peripheral vascular disease and cardiovascular disease (the most common cause of mortality in diabetes), as well as microvascular complications such as kidney disease and retinopathy

All ductal pancreatic carcinomas are GLP1R negative, whereas 6/20 PanIN 1/2 and 0/12 PanIN 3 express GLP1R

That stability lines up with recent analyst debate around Q4 results, the updated 2026 outlook, and the role of LifeMD's GLP-1 focused virtual care program in shaping long term expectations

Once Monthly GLP-1 Maridebart cafraglutide is an investigational once-monthly injectable drug developed by Amgen that shows significant promise for treating obesity and Type 2 diabetes

It is about supporting the digestive system that the medication is also affecting

New research suggests GLP-1s may reduce the risks of blood clots and early death in people with both obesity and autoimmune disease